Skip to content
Search

Latest Stories

Jeremy Meader replaces Anup Sodha as Bestway Healthcare Chief Wholesale Officer

The company announces the retirement of Lexon’s co-founder, Anup Sodha

Bestway Healthcare has appointed Jeremy Meader as its new chief wholesale officer, following the retirement of Anup Sodha.


Meader would join the company in mid-November but is expected to officially assume his responsibilities from January 2, 2024.

He will lead Lexon, Bestway Medhub, Wardle’s, Knights Fragrances, PI & Specials manufacturing and the wholesale supply chain.

Sodha, who co-founded the business 25 years ago, will continue to lead the company’s wholesale business unit until 31 December 2023.

Commenting on his retirement, Sodhi said: “I am proud of what we achieved at Lexon, it has been a team effort and I am grateful to everyone who has helped as we built a strong wholesale business.

“After almost 25 years leading the business, I am delighted with the vision and passion Bestway Group have for its future and wish them every success.”

Meader comes with over 25 years of experience in wholesale from Phoenix, Alliance Healthcare and GSK.

He was the Group Sales & Marketing Director at Phoenix before he joined the independent wholesaler.

Meader expressed gratitude after joining the company, saying: “I am absolutely delighted to be joining the Bestway family and very much looking forward to getting to know the healthcare wholesale team.

“The Bestway Group has a genuine passion, commitment and vision for the UK Healthcare sector,” he added.

“I am excited to have the opportunity to lead the healthcare wholesale business unit to deliver further growth, building on the strong heritage of the combined businesses."

Bestway's CEO, Seb Hobbs, expressed his appreciation for Anup's support during the "initial integration period" and how Anup facilitated a "smooth transition" for Lexon colleagues, customers, and the brand.

“His knowledge, love for the business and its people is evident in every conversation and we are grateful for his commitment,” he said.

“We are thrilled Jeremy Meader is joining the Bestway family and excited by the contribution he will make to further develop our healthcare wholesale offer, serve more customers and grow our business.”

Earlier this year, Well Pharmacy announced the acquisition of Lexon UK Holdings and Asurex Limited.

Lexon is a family-owned business running primarily as a pharmaceutical wholesaler for 3,000 retail pharmacy customers across the UK and Ireland.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less